CliffBio
small molecule

SIROLIMUS

SIROLIMUS

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameSIROLIMUS
Active ingredientSIROLIMUS
Strength1MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2019
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.